The CAR-TCR Summit will be held from September 4 to 7, 2018 in Boston, Massachusetts.
André Choulika, Ph.D., Chairman and Chief Executive Officer of Cellectis, and David Sourdive, Ph.D., Executive Vice President Technical Operations, to take part in this event.
Dr Choulika will participate in a panel of discussion entitled "Next Generation CAR-TCR Therapies: Executives Leaders' Fireside Chat" on September the 6th from 8:30 AM to 9:30 AM. He will then participate in another panel entitled "What are the Pros and Cons of the Various Gene Editing Technologies for CAR-TCR Therapies" from 12:00 PM to 1:00 PM.
Dr Sourdive will participate in a Deep Dive session entitled "The Future for Allogeneic Off-The-Shelf Therapies" on September the 4th from 9:00 AM to 11:00 AM. He will then participate in a panel of discussion entitled "How can we Create an Allogeneic, Virus Free Manufacturing Process?" on September the 5th from 4:10 PM to 5:10 PM.